SG11201701618SA - Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders - Google Patents
Use of tetrahydropyridines in the treatment of sodium channel related disease and disordersInfo
- Publication number
- SG11201701618SA SG11201701618SA SG11201701618SA SG11201701618SA SG11201701618SA SG 11201701618S A SG11201701618S A SG 11201701618SA SG 11201701618S A SG11201701618S A SG 11201701618SA SG 11201701618S A SG11201701618S A SG 11201701618SA SG 11201701618S A SG11201701618S A SG 11201701618SA
- Authority
- SG
- Singapore
- Prior art keywords
- tetrahydropyridines
- disorders
- treatment
- related disease
- sodium channel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG11201701618SA SG11201701618SA (en) | 2014-12-05 | 2015-11-19 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201408115SA SG10201408115SA (en) | 2014-12-05 | 2014-12-05 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
| PCT/SG2015/050461 WO2016089304A1 (en) | 2014-12-05 | 2015-11-19 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
| SG11201701618SA SG11201701618SA (en) | 2014-12-05 | 2015-11-19 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701618SA true SG11201701618SA (en) | 2017-03-30 |
Family
ID=56092099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201408115SA SG10201408115SA (en) | 2014-12-05 | 2014-12-05 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
| SG11201701618SA SG11201701618SA (en) | 2014-12-05 | 2015-11-19 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201408115SA SG10201408115SA (en) | 2014-12-05 | 2014-12-05 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10414728B2 (en) |
| EP (1) | EP3226865A4 (en) |
| JP (2) | JP6493711B2 (en) |
| AU (2) | AU2015355612B2 (en) |
| SG (2) | SG10201408115SA (en) |
| WO (1) | WO2016089304A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106431911B (en) * | 2016-09-28 | 2021-05-28 | 黄石市利福达医药化工有限公司 | Preparation and purification method of 4-felbinac |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410746B1 (en) * | 1999-04-27 | 2002-06-25 | Research Foundation Of State University Of New York, The | Metal cataltsts and methods for making and using same |
| CA2585014A1 (en) * | 2004-10-22 | 2006-05-04 | Mark Froimowitz | Methylphenidate analogs and methods of use thereof |
| ATE517623T1 (en) * | 2005-01-20 | 2011-08-15 | Inst Molecular Medicine Inc | USE OF METHYLPHENIDATE DERIVATIVES |
| US7700798B1 (en) * | 2005-06-08 | 2010-04-20 | The Research Foundation Of State University Of New York | Erogorgiaene congeners and methods and intermediates useful in the preparation of same |
| JP2009529535A (en) * | 2006-03-10 | 2009-08-20 | ザ・リサーチ・ファウンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク | Use of tetrahydropyridine in the treatment of central nervous system disorders |
-
2014
- 2014-12-05 SG SG10201408115SA patent/SG10201408115SA/en unknown
-
2015
- 2015-11-19 SG SG11201701618SA patent/SG11201701618SA/en unknown
- 2015-11-19 AU AU2015355612A patent/AU2015355612B2/en not_active Ceased
- 2015-11-19 JP JP2017530206A patent/JP6493711B2/en not_active Expired - Fee Related
- 2015-11-19 US US15/522,510 patent/US10414728B2/en not_active Expired - Fee Related
- 2015-11-19 WO PCT/SG2015/050461 patent/WO2016089304A1/en active Application Filing
- 2015-11-19 EP EP15864987.1A patent/EP3226865A4/en not_active Ceased
-
2018
- 2018-01-18 US US15/874,592 patent/US20180141907A1/en not_active Abandoned
-
2019
- 2019-01-18 JP JP2019006802A patent/JP2019070036A/en active Pending
- 2019-12-20 AU AU2019284008A patent/AU2019284008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201408115SA (en) | 2016-07-28 |
| JP2019070036A (en) | 2019-05-09 |
| AU2015355612A2 (en) | 2019-01-31 |
| AU2019284008A1 (en) | 2020-01-23 |
| US20170355676A1 (en) | 2017-12-14 |
| WO2016089304A1 (en) | 2016-06-09 |
| EP3226865A1 (en) | 2017-10-11 |
| JP6493711B2 (en) | 2019-04-03 |
| AU2015355612A1 (en) | 2017-06-29 |
| JP2017537113A (en) | 2017-12-14 |
| EP3226865A4 (en) | 2018-06-06 |
| US10414728B2 (en) | 2019-09-17 |
| AU2015355612B2 (en) | 2019-10-03 |
| US20180141907A1 (en) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265590B (en) | Keratin treatment formulations and methods | |
| IL269174A (en) | Methods for treating complement-mediated diseases and disorders | |
| IL249580A0 (en) | Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof | |
| IL254142B (en) | Tradipitant for use in the treatment of a tradipitant-responsive disease or condition | |
| IL250990A0 (en) | Human therapeutic agents | |
| PL3277280T3 (en) | Isomyosmine for use in the treatment of autoimmune diseases | |
| ZA201804950B (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| PL3160464T3 (en) | 6-hydroxybuspirone for use in the treatment of movement disorders | |
| IL246855A0 (en) | Agents for use in the treatment of retinal inflammation | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| HK1252359A1 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| IL251135A (en) | Method for the synthesis of hydroxy-triglycerides and use thereof for the prevention and treatment of diseases | |
| PL3341481T3 (en) | Microrna-328 anti-sense composition and therapeutic use | |
| SG11201701618SA (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| PT3442537T (en) | (+)-azasetron for use in the treatment of ear disorders | |
| IL250244A0 (en) | Preventing and treating inflammatory skin diseases | |
| GB201419559D0 (en) | Therapeutic compositions and methods |